Literature DB >> 23067307

How to help the aging male? Current approaches to hypogonadism in primary care.

Bruno Lunenfeld1, Stefan Arver, Ignacio Moncada, D Aled Rees, Heinrich M Schulte.   

Abstract

Hypogonadism is a common condition which occurs more frequently in older men. It is characterized by low testosterone (T) and is associated with symptoms which are often nonspecific. A key symptom is low libido, but it can also be associated with erectile dysfunction, reduced muscle mass and strength, increased body fat, reduced bone mineral density and osteoporosis, reduced vitality, and depressed mood. Hypogonadism is linked with a variety of comorbid conditions including erectile dysfunction, metabolic syndrome, diabetes, obesity, and osteoporosis. However, the condition is often underdiagnosed. T supplementation in hypogonadism is associated with a range of benefits including improved sexual function, increased lean body mass and/or reduced fat mass, and improved bone mineral density. A variety of T supplementation formulations are available. Although there is no evidence of increased risk of initiating prostate cancer with T supplementation, it is contraindicated in men with prostate cancer. It is important that primary care physicians are aware of both the signs and symptoms of hypogonadism, the monitoring and testing that is required and the merits and advantages of the various T preparations to ensure optimal management of the condition with a treatment approach that best suits patients' needs.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23067307     DOI: 10.3109/13685538.2012.729110

Source DB:  PubMed          Journal:  Aging Male        ISSN: 1368-5538            Impact factor:   5.892


  9 in total

1.  Three and six grams supplementation of d-aspartic acid in resistance trained men.

Authors:  Geoffrey W Melville; Jason C Siegler; Paul Wm Marshall
Journal:  J Int Soc Sports Nutr       Date:  2015-04-01       Impact factor: 5.150

Review 2.  The role of hypogonadism in Klinefelter syndrome.

Authors:  Christian Høst; Anne Skakkebæk; Kristian A Groth; Anders Bojesen
Journal:  Asian J Androl       Date:  2014 Mar-Apr       Impact factor: 3.285

3.  Recommendations on the diagnosis, treatment and monitoring of hypogonadism in men.

Authors:  Bruno Lunenfeld; George Mskhalaya; Michael Zitzmann; Stefan Arver; Svetlana Kalinchenko; Yuliya Tishova; Abraham Morgentaler
Journal:  Aging Male       Date:  2015-02-06       Impact factor: 5.892

4.  The prevalence of the metabolic syndrome in a farm worker community in the Boland district, South Africa.

Authors:  Maritza J Kruger; Theo A Nell
Journal:  BMC Public Health       Date:  2017-01-11       Impact factor: 3.295

5.  Approaches to male hypogonadism in primary care.

Authors:  Kristi L Lawrence; Felicia Stewart; Brandi M Larson
Journal:  Nurse Pract       Date:  2017-02-12

Review 6.  The Optimal Indication for Testosterone Replacement Therapy in Late Onset Hypogonadism.

Authors:  Yu Seob Shin; Jong Kwan Park
Journal:  J Clin Med       Date:  2019-02-07       Impact factor: 4.241

7.  Efficacy and safety of keishibukuryogan, a traditional Japanese Kampo medicine, for hot flashes in prostate cancer patients receiving androgen deprivation therapy.

Authors:  Kazuyoshi Shigehara; Kouji Izumi; Kazufumi Nakashima; Shohei Kawaguchi; Takahiro Nohara; Yoshifumi Kadono; Atsushi Mizokami
Journal:  Transl Androl Urol       Date:  2020-12

8.  Novel protein markers of androgen activity in humans: proteomic study of plasma from young chemically castrated men.

Authors:  Aniel Sanchez; Johan Malm; Aleksander Giwercman; K Barbara Sahlin; Indira Pla Parada; Krzysztof Pawlowski; Carl Fehninger; Yvonne Lundberg Giwercman; Irene Leijonhufvud; Roger Appelqvist; György Marko-Varga
Journal:  Elife       Date:  2022-03-01       Impact factor: 8.713

Review 9.  Quality of Life and Sexual Health in the Aging of PCa Survivors.

Authors:  Mauro Gacci; Elisabetta Baldi; Lara Tamburrino; Beatrice Detti; Lorenzo Livi; Cosimo De Nunzio; Andrea Tubaro; Stavros Gravas; Marco Carini; Sergio Serni
Journal:  Int J Endocrinol       Date:  2014-03-17       Impact factor: 3.257

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.